4th Quarter - Report

BOCKORNY GROUP, INC. for CVS HEALTH INC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to drug pricing Issues related to health reform proposals Issues related to representation in COVID-19-related packages HR 7213, Equitable Community Access to Pharmacist Services Act

LobbyistCovered position, as disclosed
JEFFREY MAXWELL BECKER —
DAVID BOCKORNY —
MARTIN DEPOY —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 7213 (117th)

Budget/Appropriations BUD

Issues related to hospital payments Issues related to hospital inclusion and representation in COVID-19 packages; HR 7213 Public Law Number 116-136 CARES Act H.R. 133 Consolidated Appropriations Act, 2021 H.R. 1868 An Act to prevent across-the-board direct spending cuts, and for other purposes HR 5376 Build Back Better Act Budget Reconciliation Legislative Recommendations Relating to Medicaid; Budget Reconciliation Legislative Recommendations Relating to CHIP; Budget Reconciliation Legislative Recommendations Relating to Medicare (Sec. 30801, 30803, 30804, 30805)

LobbyistCovered position, as disclosed
JEFFREY MAXWELL BECKER —
DAVID BOCKORNY —
MARTIN DEPOY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (117th), H.R. 133 (117th), H.R. 7213 (117th), H.R. 1868 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.